Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours.
NMR imaging was performed on 12 patients with cerebral tumour before and after administration of intravenous gadolinium diethylene triamine penta-acetic acid (DTPA) (0.1 mmol/kg). Contrast enhancement was seen in all cases. Ring enhancement was most frequent (7 cases) but central, linear, patchy, and diffuse enhancement were also seen with both inversion-recovery and spin-echo sequences. The degree of enhancement was greater than that seen with X-ray computed tomography (CT) in 8 cases, equal to it in 3 cases, and less in 1 case. NMR distinguished between tumour and peritumoral oedema to the same extent as did CT. No side-effects were encountered and there was no significant change in urea, creatinine and electrolytes, liver function tests, blood coagulation, or urine testing after administration of gadolinium-DTPA. Gadolinium-DTPA is likely to be of considerable value in NMR imaging of the brain.
D000328:Adult; D000368:Aged; D001929:Brain Edema / Q000175:diagnosis / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D003287:Contrast Media / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005260:Female; D005682:Gadolinium / Q000008:administration & dosage / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D004369:Pentetic Acid / Q000008:administration & dosage / Q000652:urine; D011856:Radiographic Image Enhancement; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D004369:Pentetic Acid; D005682:Gadolinium